GlassScriptPhysician profile
Jonathan P Congeni
NPI 1558523563
$3,934.85
in general payments reported to CMS, 2019-2025
34 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $62.06 · 2021: $276 · 2022: $281 · 2023: $874 · 2024: $1,134 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,043 · Education: $21.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.71 |
| Education | $21.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.22 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $468.51 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $305.87 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.29 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $131.13 | 2019-2025 | |
| Evoke Pharma, INC. | $103.72 | 2023-2025 | Gimoti |
| Ardelyx, INC. | $99.07 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $86.50 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $83.42 | 2023-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $79.11 | 2020-2024 | Ocaliva |
| Braintree Laboratories, INC. | $75.76 | 2021-2025 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $74.28 | 2024-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $68.15 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $66.52 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $61.24 | 2023-2025 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $61.17 | 2023-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $60.99 | 2022-2025 | Rebyota |
| Qol Medical, LLC | $59.07 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $58.84 | 2023-2024 | |
| Celltrion USA INC. | $56.87 | 2024-2025 | Vegzelma, Zymfentra |
| Ucb, INC. | $50.65 | 2019 | |
| Madrigal Pharmaceuticals | $43.95 | 2024-2025 | Resmetirom, Rezdiffra |
| Ironwood Pharmaceuticals, INC | $41.34 | 2022-2023 | Linzess |
| Stryker Corporation | $41.04 | 2025 | Neptune |
| Nestle Healthcare Nutrition INC. | $33.84 | 2023 | |
| Medtronic, INC. | $19.70 | 2022 | |
| Vivus LLC | $18.61 | 2025 | Qsymia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2024 | Cyltezo |
| Shionogi INC | $14.71 | 2019 | |
| Novo Nordisk INC | $14.60 | 2025 | Wegovy |
| Redhill Biopharma INC. | $14.56 | 2021 | |
| Sandoz INC. | $13.91 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $13.57 | 2021 | |
| Shire North American Group INC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Congeni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.